Macquarie Reiterates Outperform on SpaceX, $250 Price Target

1 min read Reproduced verbatim
Rating
Outperform
Unchanged
Target
$250
Unchanged
Upside
+102%
SPCX at $124 today
Macquarie and SpaceX logos

What the analyst said

Macquarie analyst Paul Golding reiterated an Outperform rating and $250 price target on SpaceX (NASDAQ: SPCX).

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

SPCX trades at $124. The 28 analysts who set a target in the last 3 months range from $75 to $800, with a median of $235. This $250 target is 6% above the median.

Since the note SPCX has moved +3% (from $120). 12-month window: day 108 of 365, closes on July 21, 2027.

Track record

This callOpen: SPCX has not reached $250 yet. This 12-month target is scored on July 7, 2027. Same target as this firm’s July 7, 2026 note, so it is scored there.

Firm track recordToo early to score Macquarie: price targets are 12-month calls and fewer than 5 of its targets are a year old. 6 of its 11 open targets have already been reached. How we score

Macquarie on SpaceX

Macquarie price targets on SpaceX

3 calls from July 7, 2026 to August 5, 2026. The target stayed at $250. The rating stayed Buy.

Macquarie targetSPCX share price
  1. August 5, 2026Kept the $250 targetBuy$250
  2. July 21, 2026 This noteKept the $250 targetBuy$250
  3. July 7, 2026Earliest call shownBuy$250
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.